{
  "docId": "019de074-6c10-759a-a503-c8b869115e9a",
  "docSlug": "3f9321c37d26dde2e5a75b53f195ef9c",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 31,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a three-column layout to categorize corporate objectives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-6c10-759a-a503-c8b869115e9a/5",
  "deckHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a",
  "deckJsonHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json",
  "deckAnchorHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.14,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. Non-GAAP profit is expected to consist of GAAP income before taxes less share-based compensation expense and non-cash interest expense. 2. The first milestone payment, of $50.0 million, will be triggered if Royalty Pharma receives $240.0 million or more in royalty payments from GSK with respect to 2023 TRELEGY global net sales, which we would expect to occur in the event TRELEGY global net sales reach approximately $2.863 billion. MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; PIFR, peak inspiratory flow rate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d9ae77a-047c-4ec7-b536-3a5ed02f41c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.375
      },
      "kind": "list",
      "text": "Expanded Capital Return Program to $325M, and expect to complete the remaining $170M this year; Generate Non-GAAP Profit in 2H'23; $50M potential milestone for TRELEGY Net Sales of ~$2.86B",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a8d8fb5-67b5-4903-acd0-ba7fba7fac4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.37,
        "y": 0.375
      },
      "kind": "list",
      "text": "Initiate Phase 3 CYPRESS trial in MSA patients with symptomatic nOH in Q1'23; Submit orphan drug designation request in early 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e732b86-2112-40ee-afba-07fca2500b8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.06,
        "y": 0.375
      },
      "kind": "list",
      "text": "Continue YUPELRI Net Sales growth by executing on targeted strategies to capture sizeable niche market; Complete PIFR-2 study and provide top-line results in 2H'23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b305ca37-b9b5-4708-b290-df5f5f4b6d62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "2023 Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6185f13b-5178-49f3-bc14-0ea4acd92b03",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Current Reality (Pain)",
      "beatSlug": "transformation-tale-current-reality-pain",
      "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}